[2] Zapatero A, Guerrero A, Maldonado X, et al. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol. 2015; 16: 320-7. [3] Dorff TB, Flaig TW, Tangen CM, et...
Prostate CancerSudden Cardiac DeathClinical OncologyFragility FractureThe article discusses research on the impact of androgen deprivation therapy (ADT) on diabetes and cardiovascular disease in men with prostate cancer. Results revealed that 1,392 ADT users compared with 1,181 nonusers developed incident...
在欧洲患者亚组，与安慰剂 + ADT + 多西紫杉醇相比，达罗鲁胺 + ADT + 多西紫杉醇三联治疗改善了患者总生存率，死亡风险降低了37% (HR 0.63, 95% CI 0.48-0.83) ，4年生存率改善(61.6% VS 43.7%) ，与总体人群一致:与安慰剂 + ADT + 多西紫杉醇组相比，达罗他胺+ ADT + 多西紫杉醇组患者至...
参考文献 [1] Spratt DE, George DJ, Shore ND, et al. Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer. JAMA Oncol. Published online March 07, 2024. doi:10.1001/jamaoncol.2023....
[9]Maribel C , Barbara B , Chiara B M , et al. Feasibility and Safety of Physical Exercise to Preserve Bone Health in Men with Prostate Cancer Receiving Androgen Deprivation Therapy: A Systematic Review. Physical Therapy. 声明 本视频/资讯/文章是由益普生医学团队编辑/医疗卫生专业人士撰写提供,...
[5]Brown J E, Handforth C, Compston J E, et al. Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. Journal of Bone Oncology, 2020, 25: 100311. ...
[1] Spratt DE, George DJ, Shore ND, et al. Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer. JAMA Oncol. Published online March 07, 2024. doi:10.1001/jamaoncol.2023.7279 作者:孙妮妮;编辑:Bree ...
heimer ’ s disease News ADT in prostate cancer and risk of Alzheimer ’ s diseaseNews ADT in prostate cancer and risk of Alzheimer ’ s diseaseBagcchi, Sanjeet
ADT not linked to excess CV mortality in prostate cancer.The article discusses research on the link between androgen-deprivation therapy (ADT) and the risk of cardiovascular (CV) death in men with unfavourable-risk prostate cancer, referencing a study by P. L. Nguyen et al in the December ...
A new study has shown that once-weekly oral bisphosphonate can prevent and improve bone loss in men undergoing androgen deprivation therapy (ADT) for prostate cancer.doi:10.1038/ncpuro0791NoneNature Clinical Practice Urology